Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harmony Biosciences excels in Q4, eyes growth in new markets

Harmony Biosciences delivered strong financial results, emphasizing growth strategies and confidence in WAKIX's revenue potential. The company is well-positioned with a focus on new prescribers, lifecycle management, and potential business development opportunities.

Harmony Biosciences excels in Q1, eyes expansion and shareholder value

Harmony Biosciences' Q1 2023 showcased strong financial performance, significant patient growth on WAKIX, and strategic plans for portfolio expansion.
The company's commercial model evolution and confidence in WAKIX's growth potential position it well for future opportunities.
Addressing challenges like patient attrition rates and regulatory concerns while exploring new business development avenues highlight Harmony's proactive approach.
With a focus on maximizing shareholder value and sustaining growth post-WAKIX, Harmony Biosciences remains poised for continued success.

Harmony Biosciences excels in Q2, eyes growth amid challenges

Harmony Biosciences delivered a strong Q2 performance, showcasing growth in net sales and patient numbers for WAKIX. The company's financial strength, strategic capital deployment, and focus on clinical development programs position it well for future growth. While facing challenges like patent disputes and market dynamics, Harmony Biosciences remains confident in its business fundamentals and growth potential.

Harmony Biosciences Achieves Record Revenue in Q3 2023

Harmony Biosciences delivered a stellar performance in Q3 2023, marked by record revenue, strong profitability, and strategic acquisitions, positioning the company for future growth.
While facing challenges in patent litigation and regulatory approvals, the company's focus on innovation, commercial excellence, and financial strength underpin its resilience.
With a clear market opportunity in narcolepsy, ongoing pipeline advancements, and a commitment to shareholder value, Harmony Biosciences remains well-positioned for long-term success.

Harmony Biosciences reports robust earnings, eyes strategic growth in 2024

Harmony Biosciences' strong financial performance, strategic acquisitions, and clinical advancements position the company for continued growth and market success.
Balancing revenue growth, pricing strategies, and clinical developments will be key focus areas for the company in navigating market challenges and opportunities.
With a focus on innovation, regulatory relationships, and financial prudence, Harmony Biosciences aims to drive sustainable growth and shareholder value in 2024.
The company's proactive approach to business development, share repurchases, and revenue guidance reflects a strategic and forward-thinking mindset for future success.

Harmony Biosciences excels in Q1, poised for long-term growth

Harmony Biosciences delivered strong financial performance in Q1, driven by WAKIX's growth and strategic acquisitions, positioning the company for continued success.
Despite operational challenges and market competition, the company's focus on innovation, rare disease treatments, and CNS franchises presents significant growth opportunities.
With a robust financial position, disciplined capital deployment, and a promising pipeline, Harmony Biosciences is poised for long-term value creation and revenue growth.
FDA recognition of unmet medical needs, positive clinical developments, and strong IP protection underscore the company's potential for market leadership and patient impact.

Harmony Biosciences reports robust Q2 performance and growth opportunities

Harmony Biosciences delivered a strong Q2 performance with revenue growth, FDA approvals, and pipeline advancements. The company's financial strength, upheld patents, and strategic growth focus position it well for future success despite some challenges.

Harmony Biosciences excels in Q3, eyes growth amid legal challenges

Harmony Biosciences demonstrated strong financial performance and pipeline progress in Q3 2024, positioning itself for continued growth.
While facing IP litigation and challenges in rare orphan categories, the company's focus on innovation and market positioning presents opportunities for future success.
Maintaining financial strength, pursuing pipeline advancements, and navigating legal hurdles will be key for Harmony Biosciences' sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Program will award funding to select applications from non-profit organizations addressing disparities in rare neurological disease and sleep disorder communities PLYMOUTH MEETING, Pa. , April 7, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological diseases, is now accepting applications for the second annual Progress at the Heart program, which funds innovative programs that address disparities, injustice, and inequities in the rare neurological disease and sleep disorder communities.

HARMONY BIOSCIENCES OPENS APPLICATIONS FOR 2022 PROGRESS AT THE HEART PROGRAM

PLYMOUTH MEETING, Pa. , April 4, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C.

HARMONY BIOSCIENCES TO PARTICIPATE IN 21st ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

PLYMOUTH MEETING, Pa. , March 31, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the company was certified as a Great Place to Work® for the fourth consecutive year.

HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FOURTH CONSECUTIVE YEAR

Funding supports the comprehensive needs of people affected by rare neurological diseases PLYMOUTH MEETING, Pa., March 17, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological diseases, today announced applications open on "World Sleep Day", Friday, March 18, 2022, for its Patients at the Heart Program.

HARMONY BIOSCIENCES ANNOUNCES APPLICATIONS OPEN MARCH 18 FOR 2022 PATIENTS AT THE HEART PROGRAM

PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its executive leaders will participate in the following upcoming virtual conferences: Oppenheimer 32nd Annual Healthcare Conference      Fireside Chat: Tuesday, March 15; 2:40 p.m.

HARMONY BIOSCIENCES TO PARTICIPATE IN TWO INVESTOR CONFERENCES IN MARCH

Harmony Biosciences is priced for limited growth past 2022 despite Wall Street projections of high growth rates through 2024. The upfront price of admission for investors looks to be disconnected from its fundamental business future. Technical buying momentum is picking up steam of late.

Harmony Biosciences: Strong Growth At A Reasonable Price

Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q4 2021 Results - Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 96.88% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass Estimates

WAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year

Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

Protagonist Therapeutics

Schrodinger 

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

3 Desirable Drug Stocks With Very Promising Pipelines

PLYMOUTH MEETING, Pa., Feb. 14, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's fourth quarter and full year 2021 financial results on Monday, February 28, 2022.

Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial Results

PLYMOUTH MEETING, Pa., Jan. 5, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C.

Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference

PLYMOUTH MEETING, Pa., Dec. 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI).

Harmony Biosciences to be Added to the Nasdaq Biotech Index

PLYMOUTH MEETING, Pa., Dec. 13, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced publication of a data analysis in the December issue of CNS Drugs that evaluates time to onset of response to pitolisant for excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy.

Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs

PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for pitolisant for the treatment of idiopathic hypersomnia (IH).

Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia

PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Linda Szyper to the Company's Board of Directors.

Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors

Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q3 2021 Results - Earnings Call Transcript

PLYMOUTH MEETING, Pa., Nov. 11, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C.

Harmony Biosciences To Participate In Two Investor Conferences In November

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 88.89% and 1.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q3 Earnings and Revenue Estimates

WAKIX® (pitolisant) Net Revenue of $80.7 Million for Third Quarter 2021 Increase of 77% vs. the Same Period in 2020

Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates

Today, we take our first in-depth look at Harmony Biosciences who IPO'd late in 2020. The company's primary compound WAKIX is seeing impressive sales growth and Harmony is already profitable.

Our First Look At Harmony Biosciences

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's third quarter 2021 financial results on Tuesday, November 9, 2021.

Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results

PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will be added to the S&P SmallCap 600® Index, effective prior to the open of trading on Friday, October 22, 2021.

Harmony Biosciences to be Added to the S&P SmallCap 600® Index

Harmony Biosciences Holdings, Inc. (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Harmony Biosciences Holdings Stock (HRMY)